Patient characteristics in those with and without KIR ligand incompatibility
| . | Without KIR ligand incompatibility, n = 113 . | With KIR ligand incompatibility (n = 62) . | P . |
|---|---|---|---|
| Recipient age, y (%) | |||
| 0-9 | 43 (38) | 22 (35) | NS |
| 10-19 | 17 (15) | 11 (18) | |
| 20-29 | 19 (17) | 6 (10) | |
| 30-39 | 21 (19) | 11 (18) | |
| 40-49 | 10 (9) | 11 (18) | |
| 50+ | 3 (3) | 1 (2) | |
| Median (range) | 17 (0.5-51) | 17 (0.6-52) | |
| Diagnosis (%) | |||
| CML | 37 (33) | 21 (34) | NS |
| ALL | 19 (17) | 16 (26) | |
| AML | 11 (10) | 3 (5) | |
| MDS | 5 (4) | 4 (6) | |
| Other leukemia | 10 (9) | 6 (10) | |
| SAA | 12 (11) | 6 (10) | |
| Immune deficiency | 15 (13) | 6 (10) | |
| Metabolic disorder | 4 (4) | 0 (0) | |
| Stage of disease malignancy | |||
| CML | NS | ||
| Chronic phase I | 22 | 10 | |
| Beyond chronic phase I | 16 | 11 | |
| Acute leukemia | |||
| CR1 | 9 | 4 | |
| CR2 | 15 | 10 | |
| CR3 | 0 | 4 | |
| Relapse | 12 | 5 | |
| Number of mismatched alleles (%) | |||
| 1 | 46 (41) | 13 (21) | NS |
| 2 | 45 (40) | 21 (34) | |
| 3 | 10 (9) | 17 (27) | |
| Greater than 3 | 6 (5) | 7 (11) | |
| Greater than 1* | 6 (5) | 4 (7) | |
| GVHD prophylaxis (%) | |||
| T-cell depletion | 42 (37) | 18 (29) | NS |
| Cyclosporine-based ± MTX | 71 (63) | 44 (71) | |
| Preparative Regimen | |||
| TBI/Cy ± others | 101 | 56 | NS |
| Bu/Cy ± others | 12 | 6 | |
| Donor age, y, median (range) | 37 (22-53) | 37 (19-56) | NS |
| . | Without KIR ligand incompatibility, n = 113 . | With KIR ligand incompatibility (n = 62) . | P . |
|---|---|---|---|
| Recipient age, y (%) | |||
| 0-9 | 43 (38) | 22 (35) | NS |
| 10-19 | 17 (15) | 11 (18) | |
| 20-29 | 19 (17) | 6 (10) | |
| 30-39 | 21 (19) | 11 (18) | |
| 40-49 | 10 (9) | 11 (18) | |
| 50+ | 3 (3) | 1 (2) | |
| Median (range) | 17 (0.5-51) | 17 (0.6-52) | |
| Diagnosis (%) | |||
| CML | 37 (33) | 21 (34) | NS |
| ALL | 19 (17) | 16 (26) | |
| AML | 11 (10) | 3 (5) | |
| MDS | 5 (4) | 4 (6) | |
| Other leukemia | 10 (9) | 6 (10) | |
| SAA | 12 (11) | 6 (10) | |
| Immune deficiency | 15 (13) | 6 (10) | |
| Metabolic disorder | 4 (4) | 0 (0) | |
| Stage of disease malignancy | |||
| CML | NS | ||
| Chronic phase I | 22 | 10 | |
| Beyond chronic phase I | 16 | 11 | |
| Acute leukemia | |||
| CR1 | 9 | 4 | |
| CR2 | 15 | 10 | |
| CR3 | 0 | 4 | |
| Relapse | 12 | 5 | |
| Number of mismatched alleles (%) | |||
| 1 | 46 (41) | 13 (21) | NS |
| 2 | 45 (40) | 21 (34) | |
| 3 | 10 (9) | 17 (27) | |
| Greater than 3 | 6 (5) | 7 (11) | |
| Greater than 1* | 6 (5) | 4 (7) | |
| GVHD prophylaxis (%) | |||
| T-cell depletion | 42 (37) | 18 (29) | NS |
| Cyclosporine-based ± MTX | 71 (63) | 44 (71) | |
| Preparative Regimen | |||
| TBI/Cy ± others | 101 | 56 | NS |
| Bu/Cy ± others | 12 | 6 | |
| Donor age, y, median (range) | 37 (22-53) | 37 (19-56) | NS |
NS indicates not significant, P > .2; CML, chronic myelocytic leukemia; ALL, acute lymphocytic leukemia; AML, acute myelocytic leukemia; MDS, myelodysplastic syndrome; SAA, severe aplastic anemia; CR, complete remission; MTX, methotrexate; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan.
Typing adequate to assign KIR status, missing allele level typing at one locus.